ArticleAntimicrobial agents and chemotherapy2024
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.AIDS (London, England) · 2025Trial
- Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.Antimicrobial agents and chemotherapy · 2024Trial
- The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections.Viruses · 2025Article
- Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible.Le infezioni in medicina · 2025Article
- Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.AIDS research and human retroviruses · 2024Article
- Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.Antimicrobial agents and chemotherapy · 2024Article
- Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023).Frontiers in public health · 2024Article
- Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine.Open forum infectious diseases · 2023Article
- Long-acting antiretrovirals and HIV treatment adherence.The lancet. HIV · 2023Review
- Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?Therapeutic advances in infectious diseaseReview
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.